Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients undergoing Coronary Artery Bypass Surgery. A prospective randomized controlled study.

Completed

• Conditions: 10011082; 10007593

• Registration Number: NL-OMON29792
• Lead Sponsor: Catharina-ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

Patients who are using clopidogrel at least 5 days before surgery with a dose of 75mg clopidogrel without loading dose, with or without concomitant use of aspirin. Or patients who received a loading dose of 300-600mg clopidogrel 24 hours before CABG, with or without concomitant use of aspirin

Exclusion Criteria

concomitant use of coumarine/heparine derivates; pre-existing bleeding disorders; thrombocytopenia; renal and hepatic failure; end-stage heart failure; emergency bypass surgery; concomitant valvular or other cardiac procedures; re-operation; off-pump CABG

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Blood loss, transfusions and rethoracotomies.<br /><br>Predictive value of TEG</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Death, myocardial infarction, stroke, respiratory failure, renal failure<br /><br>requiring dialysis, mediastinitis, wound infection, readmission rates within 30<br /><br>days from discharge, and ICU and hospital lengths of stay</p><br>